Collaborations & Alliances
Related Searches:
Filter by:
571 - 585 of 1091 results
July 7, 2010
Aquapharm Biodiscovery, a marine biotechnology company, has signed a research agreement with Albany Molecular Research (AMRI) to identify novel drug-like compounds and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm’s col
Read More »
July 1, 2010
Eisai Inc., the U.S. operation of Tokyo-based Eisai Co., Ltd., has entered into an agreement with Arena Pharmaceuticals for exclusive U.S. rights to commercialize lorcaserin, a drug candidate for potential treatment of obesity, including weight loss.
Read More »
June 28, 2010
MorphoSys AG and Xencor, Inc. have signed an exclusive worldwide license and collaboration agreement for an antibody in Phase I development.
Read More »
June 24, 2010
TraceLink, Inc. and Catalent Pharma Solutions have entered a partnership aimed at improving production visibility for Catalent customers across their entire manufacturing and packaging product lifecycle.
Read More »
June 23, 2010
Prosensa has initiated two further programs under its alliance with GlaxoSmithKline covering novel RNA-based treatments for Duchenne Muscular Dystrophy (DMD).
Read More »
June 22, 2010
Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) has signed an exclusive agreement with Diamyd Medical AB to develop and commercialize Diamyd’s GAD65 antigen-based therapy for the treatment and prevention of type 1 diabetes and associated conditio
Read More »
June 22, 2010
Sanofi-Aventis and Regulus, Inc. have entered into a global strategic alliance to discover, develop, and commercialize microRNA therapeutics.
Read More »
June 21, 2010
Focus on internal pipeline leads BMS to return MET inhibitor to partner
Read More »
June 17, 2010
Bayer Schering Pharma and OncoMed Pharmaceuticals entered into a global strategic alliance to discover, develop and commercialize anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.
Read More »
June 17, 2010
Evotec AG has received a $3.1 million milestone payment through its research alliance with Boehringer Ingelheim.
Read More »
June 16, 2010
$75 million upfront for post-IIb oral hormone antagonist
Read More »
June 11, 2010
Patheon has signed an expanded contract manufacturing agreement with Merck.
Read More »
June 8, 2010
Hospira and Durect Corp. have entered into a licensing agreement to develop and market Durect’s Posidur (SABER-bupivacaine), a long-acting version of the anesthetic bupivacaine, currently in Phase III trials.
Read More »
June 8, 2010
TransTech Pharma and Forest Laboratories have entered into a license agreement for the development and commercialization of small molecule compounds discovered by TransTech.
Read More »
June 7, 2010
Immunovaccine, Inc. has signed a collaborative research agreement with Vaxil BioTherapeutics to explore the efficacy of Vaxil's cancer antigens in Immunovaccine's DepoVax vaccine enhancement platform.
Read More »
571 - 585 of 1091 results
